On CNBC's Fast Money Final Trade, Tim Seymour said that Gilead Sciences, Inc. GILD looks cheap at 7 times price-to-earnings multiple. He sees it as a relative value and the best way to play the sector.
Steve Grasso would buy iShares NASDAQ Biotechnology Index (ETF) IBB and Pfizer Inc. PFE.
Guy Adami said IBB bounced off $240 on Monday, and now he believes that the risk reward sets up really well for the stock. He added that politicians haven't been talking about biotech companies for a couple of weeks.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in